Clinical evaluation of 5-bromo-5-fluoro-6-methoxy-dihydro-2'-deoxyuridine.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000818:Animals; D001973:Bromodeoxyuridine / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D003857:Deoxyuridine / Q000097:blood / Q000627:therapeutic use* / Q000633:toxicity / Q000652:urine; D004285:Dogs; D005260:Female; D005467:Floxuridine / Q000627:therapeutic use*; D005706:Gallbladder Neoplasms / Q000188:drug therapy; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007080:Ileocecal Valve; D007414:Intestinal Neoplasms / Q000188:drug therapy; D008113:Liver Neoplasms; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D012004:Rectal Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D013274:Stomach Neoplasms / Q000188:drug therapy
D005467:Floxuridine; D001973:Bromodeoxyuridine; D003857:Deoxyuridine